Literature DB >> 16670346

Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination.

Hiroyoshi Nishikawa1, Feng Qian, Takemasa Tsuji, Gerd Ritter, Lloyd J Old, Sacha Gnjatic, Kunle Odunsi.   

Abstract

We have recently reported that NY-ESO-1-specific naive CD4+ T cell precursors exist in most individuals but are suppressed by CD4+CD25+ regulatory T cells (Tregs), while memory CD4+ T cell effectors against NY-ESO-1 are found only in cancer patients with spontaneous Ab responses to NY-ESO-1. In this study, we have analyzed mechanisms of CD4+ T cell induction following peptide vaccination in relation to susceptibility to Tregs. Specific HLA-DP4-restricted CD4+ T cell responses were elicited after vaccination with NY-ESO-1(157-170) peptide (emulsified in IFA) in patients with NY-ESO-1-expressing epithelial ovarian cancer. These vaccine-induced CD4+ T cells were detectable from effector/memory populations without requirement for in vitro CD4+CD25+ T cell depletion. However, they were only able to recognize NY-ESO-1(157-170) peptide but not naturally processed NY-ESO-1 protein and had much lower avidity compared with NY-ESO-1-specific pre-existing naive CD4+CD25- T cell precursors or spontaneously induced CD4+ T cell effectors of cancer patients with NY-ESO-1 Ab. We propose that vaccination with NY-ESO-1(157-170) peptide recruits low-avidity T cells with low sensitivity to Tregs and fails to modulate the suppressive effect of Tregs on high-avidity NY-ESO-1-specific T cell precursors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16670346     DOI: 10.4049/jimmunol.176.10.6340

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  HLA-F is a surface marker on activated lymphocytes.

Authors:  Ni Lee; Akiko Ishitani; Daniel E Geraghty
Journal:  Eur J Immunol       Date:  2010-08       Impact factor: 5.532

2.  Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity.

Authors:  Kimberly R Jordan; Rachel H McMahan; Jason Z Oh; Matthew R Pipeling; Drew M Pardoll; Ross M Kedl; John W Kappler; Jill E Slansky
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

Review 3.  The opposing roles of CD4+ T cells in anti-tumour immunity.

Authors:  Tomasz Ahrends; Jannie Borst
Journal:  Immunology       Date:  2018-04-27       Impact factor: 7.397

4.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

Authors:  Daisuke Sugiyama; Hiroyoshi Nishikawa; Yuka Maeda; Megumi Nishioka; Atsushi Tanemura; Ichiro Katayama; Sachiko Ezoe; Yuzuru Kanakura; Eiichi Sato; Yasuo Fukumori; Julia Karbach; Elke Jäger; Shimon Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

5.  Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.

Authors:  Rachel Lubong Sabado; Anna Pavlick; Sacha Gnjatic; Crystal M Cruz; Isabelita Vengco; Farah Hasan; Meredith Spadaccia; Farbod Darvishian; Luis Chiriboga; Rose Marie Holman; Juliet Escalon; Caroline Muren; Crystal Escano; Ethel Yepes; Dunbar Sharpe; John P Vasilakos; Linda Rolnitzsky; Judith Goldberg; John Mandeli; Sylvia Adams; Achim Jungbluth; Linda Pan; Ralph Venhaus; Patrick A Ott; Nina Bhardwaj
Journal:  Cancer Immunol Res       Date:  2015-01-29       Impact factor: 11.151

6.  MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells.

Authors:  Courtney L Erskine; Christopher J Krco; Karen E Hedin; Nancy D Borson; Kimberly R Kalli; Marshall D Behrens; Sabrina M Heman-Ackah; Eric von Hofe; Peter J Wettstein; Mansour Mohamadzadeh; Keith L Knutson
Journal:  J Immunol       Date:  2011-05-25       Impact factor: 5.422

7.  Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.

Authors:  Shigehisa Kitano; Takemasa Tsuji; Caillian Liu; Daniel Hirschhorn-Cymerman; Chrisann Kyi; Zhenyu Mu; James P Allison; Sacha Gnjatic; Jianda D Yuan; Jedd D Wolchok
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

8.  Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells.

Authors:  Tao Dao; Tatyana Korontsvit; Victoria Zakhaleva; Kurtis Haro; Jonathan Packin; David A Scheinberg
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

9.  NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.

Authors:  Sacha Gnjatic; Nasser K Altorki; Derek Ng Tang; Shi-Ming Tu; Vikas Kundra; Gerd Ritter; Lloyd J Old; Christopher J Logothetis; Padmanee Sharma
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

10.  Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2.

Authors:  Kerrington R Molhoek; Chantel C McSkimming; Walter C Olson; David L Brautigan; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2008-10-08       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.